NurExone Announces Closing of Non-Brokered Private Placement

TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,012,573 units (“Units”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “Offering”). The Company intends to use the proceeds of the Offering for general working capital purposes. No insiders participated in this Offering and no finder’s fees were paid in connection with this Offering.